Combining taxanes with radiation for solid tumors

International Journal of Cancer

Volumn 90, Issue 3, 2000, Pages 113-127

  Choy, Hak ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDROXYUREA; MARIMASTAT; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; ESOPHAGITIS; ESOPHAGUS CANCER; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0033948534     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000620)90:3<113::AID-IJC1>3.0.CO;2-C     Document Type: Review

References (135)

1. Le Chavalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: First analysis of randomized trials in 353 patients. J Natl Cancer Inst 1991;83:417-423,
2. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996;14:3156-3174.
3. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
4. Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M, Kaye S. Docetaxel. An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995;87:676-681.
5. Belani CP, Aisner J. Hiponia D, Engstrom C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non small cell lung cancer. Semin Oncol 1995;22(suppl 9):7-12.
6. Cerny T. Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, Van Meerbeek J, Wanders J, Franklin HR, Kaye S. Docetaxel (Taxotere) is active in non-small-cell lung cancer. A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994;70:384-387.
7. Manfredi JJ, Parness J, Horwitz SB. Taxon binds to cellular microtubules. J Cell Biol 1982;94:688-696.
8. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479-487.
9. Gueritte-Voegelein F, Guenard D, Lavelle F. Le Goff MT, Mangatal L, Polier P. Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 1991;34:992-998.
10. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-1565.
11. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-1314.
12. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3:2431-2438.
13. Choy H, Rodriguez. FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of Taxol as a potential radiation sensitizer. Cancer 1993;71:3774-3778.
14. Geard CR, Jones JM. Radiation and Taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 1994;29:565-569.
15. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-146.
16. Minarik L, Hall EJ. Taxol in combination with acute and low dose rate irradiation. Radiother Oncol 1994; 32;124-128.
17. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992a;22:613-617.
18. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-3497.
19. Choy H, Rodriguez F, Koester S, Degan D. Radiation sensitizing effects of Taxotere (RP 56976). Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research, May 1992 Vol. 33: 500.
20. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys 1994;29:559-564.
21. Zanelli GD, Quaia M, Robieux I, Bujor L, Santarosa M, Favaro D, Spada A, Caffau C, Gobitti C, Trovo MG. Paclitaxel as a radiosensitizer: A proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 1997;33:486-492.
22. Liebmann J, Herscher L, Fisher J, et al. Antagonism of paclitaxel cytotoxicity by x-rays: Implications for the sequence of combined modality therapy. Int J Oncol 1996;8:991-996.
23. Van Rijn J, van den Berg J, Meijer OW. Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. Int J Radiat Oncol Biol Phys 1995;33:635-639.
24. Griffon-Etienne G, Merlin J-L. Marchal C. In vitro evaluation of Taxol combined with radiation in human squamous cell carcinoma spheroids. Cancer Lett 1996; 109:23-32.
25. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996;56:1842-1850.
26. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996;56:5198-5204.
27. Ingram ML, Redpath JL. Subadditive interaction of radiation and Taxol in vitro. Int J Radiat Oncol Biol Phys 1997;37:1139-1144.
28. Gupta N, Hu LJ, Deen DF. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Radiat Oncol Biol Phys 1997;37:885-895.
29. Stromberg JS, Lee YJ, Armour EP, Martinez AA, Corry PM. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 1995;75:2262-2268.
30. Steren A, Sevin BU, Perras J, Angioli R. Nguyen H, Guerra L, Koechli O, Averette HE. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 1993;48:252-258.
31. Rodriguez M, Sevin BU, Perras J, Nguyen HN, Pham C, Steren AJ, Koechli OR, Averette HE. Paclitaxel: A radiation sensitizer of human cervical cancer cells. Gynecol Oncol 1995;57:165-169.
32. Jaakkola M, Rantanen V, Gremnan S, Kulmala J, Grenman R. In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma-cell lines. Cancer 1996;77:1940-1946.
33. Lokeshwar BL, Ferrell SM, Block NL. Enhancement of radiation response of prostatic carcinoma by Taxol: Therapeutic potential for late-stage malignancy. Anti-cancer Res 1995;15:93-98.
34. Lerner NJ. Concomitant hydroxyurea and irradiation: Clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania Hospital. Am J Surg 1977:134:505-509.
35. Panis X, Nguyen T. Froissart D, Demauge L. Hyperfractionated radiotherapy with or without misonidazole: Results of a prospective randomized study in Stage III-IV squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1984;6:1845-1849.
36. Lee DJ, Pajak TF, Stet J, Order SE, Weissberg JB, Fischer JJ. A Phase I/II study of the hypoxic cell sensitizer misonidazole as adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: A RTOG randomized study. (#79-04). Int J Radiat Oncol Biol Phys 1989;16:465-470.
37. Slotman GJ, Cummings FJ, Glocksman AS, Doolittle CO, Leone LA. Preoperative simultaneously administered cis-platinum plus radiation therapy for advanced squamous cell carcinoma of the head and neck. Head Neck Surg 1987;8:159-164.
38. Glicksman AS, Slotman G, Doolittle C, Clark J, Koness J, Coachman N, Posner M, DeRosa E, Wanebo H. Concurrent cis-platinum with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1994;30:1043-1050.
39. Crissman JD, Pajak TF, Zarbo RJ, Marciel VA, Surraf M. Improved response and survival to combined cisplatin and radiation in non-keratinizing squamous cell carcinomas of the head and neck: An RTOG study of 114 advanced stage tumors. Cancer 1987;59:1391-1397.
40. Taylor SG, 4th, Murphy AK, Caldarelli DD, Showel JL, Kie K, Griern KL, Mittal BB, Kies M. Hutchinson JC Jr., Holinger LD. Combined simultaneous cisplatin/fluorouracil chemotherapy, and split course radiation in head and neck cancer. J Clin Oncol 1989;7: 846-856.
41. Adelstein DJ, Sharan VM, Earle AS, Shah AC, Vlastou C, Haria CD, Damm C, Carter SG, Hines JD. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. Cancer 1990;65:1685-1691.
42. Douple EB, Eaton WL, Tulloh ME. Skin radiosensitization studies using combined cis-dichlorodiammineplatinum (II) and radiation. Int J Radiat Oncol Biol Phys 1979;5:1383-1385.
43. Haselow RE. Adams GL, Oken MM, et al. Cisplatinum (DDP) with radiation therapy (RT) for locally unresectable head and neck cancer. Proc Am Soc Clin Oncol 1983;2:169.
44. Amrein PC, Wang CC, Daly M, McIntyre J, Faban R. Concurrent Taxol and BID radiotherapy in patients with advanced stage squamous cell carcinoma of the head and neck (abstract 1548). Proc Am Soc Clin Oncol 1998;17:402a.
45. Kroog GS, Van Waes C, Thomas G, Ondry F, Smith C, Duffey D, Cook JA, Mitchell JB, Herscher LL. A pilot study of 120-hour paclitaxel with radiation therapy for locally advanced head and neck cancer (abstract 1528). Proc Am Soc Clin Oncol 1998;17:396a.
46. Machtay M, Rosenthal DL, Aviles V, Treat J, Weinstein GS, Weber RS, Kligerman MM. A phase I trial of 96-hour Taxol infusion plus accelerated radiotherapy for unresectable head and neck cancer (abstract 1524). Proc Am Soc Clin Oncol 1998;17:395a.
47. Steinberg L, Hassen M, Hoppel C, Sharan V, Olmsted L, Strauss M, Stepnick D, Sabri A, Mackay W, Subramanyan S, Maniglia A. A phase I study of radiotherapy and simultaneous paclitaxel in patients with locally advanced squamous cell carcinoma of the head and neck (abstract 913). Proc Am Soc Clin Oncol 1996;15:321.
48. Chougule P, Wanebo H, Akhtar M, Leone L, McRae R, Nigri P, Safran H, Koness RJ, Radie-Keane K, Akerley W, Cole B. Concurrent paclitaxel carboplatin and radiotherapy in advanced head and neck cancers: A phase II study (abstract 1468). Proc Am Soc Clin Oncol 1998;17:381.
49. Gonzalez MF, Clowney BW. Cafferty B, Chang WW. Phase II trial of concomitant carboplatinum and paclitaxel with radiation therapy followed by cisplatin, fluorouracil and Interferon alpha-2a in unresectable head and neck carcinoma (abstract 1525). Proc Am Soc Clin Oncol 1998;17:395a.
50. Brockstein B, Haraf DJ. Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel tluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998;16:735-744.
51. Vokes EE. A phase II study of paclitaxel, fluorouracil, hydroxyurea and twice-daily radiotherapy with filgrastim support for locoregionally advanced head and neck cancer. The Fox Chase Cancer Center and Free University Hospital Paclitaxel Investigators' Workshop and Consensus Conference. St. Thomas, US Virgin Islands. March 26-28, 1998, Oral.
52. Colevas AD, Busse PM, Morris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial. J Clin Oncol 1998;16:1331-1339.
53. DFCI-95041. Phase I study of docetaxel plus concurrent radiotherapy after induction chemotherapy for squamous cell cancer of the head and neck. Study protocol. Available at: http://cancernet.nci.nih.gov/cgi-bin. Accessed February 22, 1999.
54. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: A meta-analysis. Ann Intern Med 1996; 125:723-729.
55. Dillman RO, Seagren SL, Proper! KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF 3rd, Green MR. A randomized trial of induction chemotherapy plus highdose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:945-945.
56. Schaake-Koning C, Van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, Van Houtte P, Koolen M, Maat B, Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
57. Sause WT, Scott C. Taylor S, Johnson D, Livingston R, Komaki R, Emani B, Curran WJ, Byhardt RW, Turrisi AT. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a Phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87: 198-205.
58. Fossella FV, Lee JS, Murphy WK, el al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:1238-1244.
59. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232-1237.
60. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, DeVore RF 3rd. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial. J Clin Oncol 1996;14:2054-2060.
61. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced NSCLC: A Japanese Cooperative study. J Clin Oncol 1996;14:1649-1655.
62. Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable. locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001. Semin Oncol 1997;24(suppl 12):SIV89SIV95.
63. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75: 968-972.
64. Rigas JR. Docetaxel in stage III and stage IV non-small cell lung cancer. Eur J Cancer 1995;31A:S18-S20.
65. Vafai D. Israel Z, Zaretsky S, Natale RB. Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer (NSCLC) (abstract 1067). Proc Am Soc Clin Oncol 1995;14:352.
66. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 1994;12:2682-2686.
67. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998;4:1931-1936.
68. Lau DH, Ryu JK, Gandara DR, Morgan R, Doroshow J, Wilder R, Leigh B. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin Oncol 1997;24(suppl 12):S12/106-S12/109.
69. Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H. A phase I/II study of paclitaxel (Taxol) and concurrent radiotherapy in advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1997;39: 1107-1111.
70. Rathmamn J, Rigas JR, Leopold KA, Maurer LH, Eaton W Jr, Black W, Smith EL, Meyer LP, Hammond SM. Daily paclitaxel and thoracic radiation therapy for the treatment of stage II and III non-small cell lung cancer (NSCLC) (abstract 1722). Proc Am Soc Clin Oncol 1997;16:478a.
71. Choy H, DeVore RD, Hande KR, Porter LL, Rosenblatt PA, Yunus F, Schlabach L, Smith C, Meshad MW, Shyr Y, Johnson DH. Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperative non-small cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) trial (abstract 1794). Proc Am Soc Clin Oncol 17:467a, 1998. Poster presented at the
72. Choy H, DeVore RD, Hande KR, Porter LL, Rosenblatt PA, Yunus F, Schlabach L, Smith C, Meshad MW, Shyr Y, Johnson DH. Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperative non-small cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) trial (abstract 1794). Proc Am Soc Clin Oncol 17:467a, 1998. Poster presented at the Thirty-Fourth Annual Meeting of the American Society of Clinical Oncology, May 10-19, 1998, Los Angeles, CA.
73. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced nonsmall-cell lung cancer. J Clin Oncol 1998;16:3316-3322.
74. Belani CP. Paclitaxel and carboplatin for reseclable and locally advanced NSCLC. The Fox Chase Cancer Center and Free University Hospital Paclitaxel Investigators' Workshop and Consensus Conference. St. Thomas, US Virgin Islands, March 26-28, 1998. Oral Presentation.
75. Socinski MA, Clark JA, Halle J, Steagall A, Kaluzny B, Rosenman JG. Induction therapy with carboplatin/ paclitaxel followed by concurrent carboplatin/ paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced unresectable nonsmall cell lung cancer: Preliminary report of a phase I trial. Semin Oncol 1997;24(suppl 12):SIVI17-SIV122.
76. Socinski M. Paclitaxel/carboplatin and conformal RT in non-small cell lung cancer. The Fox Chase Cancer Center and Free University Hospital Paclitaxel Investigators' Workshop and Consensus Conference. St. Thomas, US Virgin Islands, March 26-28, 1998. Oral Presentation.
77. Greco FA, Stroup SL, Gray JR, Hainsworth JD. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 1996;14:1642-1648.
78. Belani CP, Rarnanathan RK. Combined modality treatment of locally advanced non-small cell lung cancer: Incorporation of novel chemotherapeutic agents. Chest 1998;113:53S-60S.
79. Bunn PA Jr., Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Semin Oncol 1998;25:(suppl 9):2-10.
80. NCI-96-C-0054. Phase II study of neoadjuvant continuous-infusion TAX plus bolus CDDP followed by thoracic radiotherapy for stage III non-small cell lung cancer. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
81. UCMC-967222, NCI-V97-1331, ALZAUCMC-967222. Phase II study of amifostine with paclitaxel, carboplatin and concurrent radiation therapy for unresectable stage II, IIIA, and all stage IIIB non-small cell lung cancer. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
82. RTOG-9801. Phase III randomized study of amifostine mucosal protection in patients with favorable performance inoperable stage II IIIA or IIIB non-small cell lung cancer receiving sequential induction and concurrent hyperfractionated radiotherapy with paclitaxel and carboplatin. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
83. TJUH-969139. Phase II study of induction paclitaxel plus carboplatin followed by thoracic radiation therapy with concurrent paclitaxel and amifostine for unresectable locally advanced or partially resected non-small cell lung cancer. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
84. CLB-9534. Phase II study of TAX/CBDCA followed by concomitant chemoradiotherapy for inoperable stage IIIA/B non-small cell lung cancer. Study protocol. Available at http://cancernel.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
85. CLB-39801. Phase III randomized study of concurrent carboplalin, paclitaxel, and radiation therapy with or without prior induction carboplatin and paclitaxel in patients with unresectable stage III non-small cell lung cancer. Study protocol. Available at http:// cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
86. Vokes EE, Leopold KA, Hernodon JE II, Crawford J, Cooper MR, Clamon G, Epstein JM, Green MR. A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage IIIB non-small cell lung cancer: Feasibility data (CALGB study #9431) (abstract 1636). Proc Am Soc Clin Oncol 1997;16:455a.
87. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Colomb HM, Vokes EE. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1988;16:159-164.
88. Teng M, Choy H, DeVore RD, Hande KR, Arteaga CL, Porter LL, Rosenblatt PA, Slovis B, Laporte K, Shyr Y, Johnson DH. Phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) trial (abstract 1938). Proc Am Soc Clin Oncol 1998;17:503a.
89. Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose intensities. J Clin Oncol 1997;15:3464-3470.
90. Bremnes RM, Sundstrom S, Aasebo U, et al. Treatment of limited small cell lung cancer (SCLC) with paclitaxel, cisplatin, etoposide and radiation therapy (abstract). Lung Cancer 1997;18(suppl 1):54.
91. Nathan Levitan, Afshin Dowlati, Donald Shina, Mark Craffey, Wilma Mackay, Russell DeVore, James Jett, Scot C. Ramick, Alex Chang, David Johnson. MultiInstitutional Phase I/II Trial of Paclitaxel, Cisplatin, and Etoposide With Concurrent Radiation for Limited-Stage Small-Cell Lung Carcinoma. Journal of Clinical Oncology, Vol 18, Issue 5 (March), 2000: 1102.
92. Bremnes RM, Sundstrom S, Aasebo U, Vilsvik J. Paclitaxel in combination with cisplatin, etoposide and thoracic radiotherapy for limited small cell lung cancer (SCLC): A phase II study (abstract 1826). Proc Am Soc Clin Oncol 1998;17:475a.
93. Bonomi P. Review of selected randomized trials in small cell lung cancer. Semin Oncol 1998;25(4 suppl 9):70-78.
94. Cahan MA, Walter KA, Colvin OM, Brem H. The cytotoxicity of paclitaxel in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 1994;33:441-444.
95. Walter KA, Cahan MA, Gur A, Tyler BM, Hilton J, Colvin OM, Burger PC, Domb AB, Brem H. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 1994;54:2207-2212.
96. Helson L, Helson C. Malik S, et al. A saturation threshold for Taxol cytotoxicity in human glial and neuroblastoma cells. Anticancer Drugs 1993;4:487-490.
97. Riondel J, Jacrot M, Fessi M, et al. Effects of free and liposome-encapsulated paclitaxel on two brain tumors xenografted into nude mice. In Vivo 1992;6:23-27.
98. Riondel J, Jacrot M, Picot F, et al. Therapeutic response to paclitaxel of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 1986; 17:136-142.
99. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966;29:450-474.
100. Lederman G, Odaimi M, Fine M, Wertheim S, Lowry J, Wrzolek M, Radhid H, Quan G, Lombardi E, Arbit E. Recurrent glioblastoma multiforme: Potential benefits using fractionated stereotactic radiosurgery and concurrent Taxol (abstract 1441). Proc Am Soc Clin Oncol 1997;16:404a.
101. Glantz MJ, Choy H, Kearns CM, Cole BF, Mills P, Zuhowski EG, Saris S, Rhodes CH, Stopa E, Egorin MJ. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 1996;14:600-609.
102. Glantz M, Choy H. Weekly Paclitaxel With and Without Concurrent Radiation Therapy: Toxicity, Pharmacokinetics, and Response. Seminars in Oncology 1996;23:5, 12 14-18.
103. Glantz MJ, Chamberlain MC, Chang SM, Prados MD, Cole BF. The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol 1999;9(2 suppl 1):27-33.
104. RTOG-9602. Phase II study of weekly paclitaxel and conventional radiation therapy for supratentorial glioblastoma multiforme. Available at http://cancernet.nci. nih.gov/cgi-bin.
105. Glantz MJ, Choy H. Chakravarthy A, Cmelak AJ, Curran WJ, Porter LL, Rosenblatt PA, Moots PL, La Porte KL, Shyr Y, Johnson DH. A Randomized Phase III Trial of Concurrent Paclitaxel and Whole Brain Radiotherapy (WBRT/) VS. WBRT Alone for Brain Metastases. Proceedings of the 35 Annual Meeting of the American Society of Clinical Oncology, May, 1999. Vol. 18, p. 140.
106. Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhaurer E. Phase H trial of docetaxel in patients with recurrent malignant glioma: A study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 1996;14: 203-206.
107. Herrington JD, DiNunno L, Reinhart JJ. Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis. Ann Pharmacother 1998;32:611-612.
108. Safran H, Gaissert H, Akerman P, Hesketh PJ, Koness J, Radie-Keane K, Ready N, Fellows H, Akhtar M, Triedman S, Cicchetti GM, Graziano S, Bogart J, Sambandam S, Thomas A., Kornmehi E, McAnaw R, Wanebo H. Neoadjuvant paclitaxel, cisplatin and radiation for esophageal cancer (abstract 994). Proc Am Soc Clin Oncol 1998;17:259a.
109. Bernard S, Poole M, Socinski M, Detterbeck F, Egan T, Jones D, Steagall A, King L. Schell M, Tepper J. Paclitaxel combined with 5-fluorouracil and cisplatin concomitant with radiotherapy in locally advanced or metastatic esophageal cancer-Preliminary report of a phase I/II trial (abstract 1102). Proc Am Soc Clin Oncol 1998;17:286a.
110. Lynch TJ, Choi N, Wright C, Grossbard ML, Wain J, Brugge W, Carey RW, Grillo H, Mathisen DJ. A phase I/II trial of preoperative Taxol, cisplatin, 5FU and concurrent boost radiation in esophageal cancer (abstract 928). Proc Am Soc Clin Oncol 1997;16:261a.
111. Blanke C, Chiappori A, Epstein B. Choy H, Leach S, Beauchamp RD, Pierson R, Sawyers J, DeVore R, Johnson DH. A phase II trial of neoadjuvant paclitaxel and cisplatin with radiotherapy, followed by surgery and postoperative Taxol with 5-fluorouracil and leucovorin in patients with locally advanced esophageal cancer (abstract 1006). Proc Am Soc Clin Oncol 1997; 16:283a.
112. Weiner LM, Colarusso P, Goldberg M, Dresier C, Coia LR. Combined-modality therapy for esophageal cancer: Phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and highdose radiation before esophagectomy. Semin Oncol 1997;24(suppl 19):S19-93-S19-95.
113. MSKCC-97088. Phase II Study of preoperative cisplatin and paclitaxel followed by radiation therapy with concurrent cisplatin and paclitaxel and then surgery for localized esophageal carcinoma. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
114. MSKCC-95073A4. Phase I study of TAXI CDDP concurrent with radiotherapy and of TAXI CDDP preceding and concurrent with radiotherapy for localized esophageal cancer. Study protocol. Available at http:// cancernet.nci, nih.gov/cgi-bin. Accessed February 16, 1999.
115. UNC-LCCC-9622, Phase I/II study of paclitaxel/ fluorouracil/cisplatin concurrent with radiotherapy for locally advanced or metastatic esophageal cancer. Study protocol. Available at http://cancernet.nci.nih. gov/cgi-bin. Accessed February 16, 1999.
116. Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study. J Clin Oncol 1997;15:901-907.
117. Safran H, Akermam P, Cioffi W, Gaissart H, Joseph P, King T, Hesketh PJ, Wanebo H. Paclitaxel and concurrent radiation for locally advanced adenocarcinomas of the pancreas, stomach and GE junction. Semin Radiat Oncol 1999;9(2 suppl 1):53-57.
118. BRUOG-PG-38/P. Phase II study of paclitaxel and radiotherapy followed by surgical resection for pancreatic adenocarcinoma. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
119. RTOG-9812. Phase II study of external irradiation and weekly paclitaxel in patients with nonmetastatic unresectable pancreatic cancer. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
120. BRUOG-PG-38/G. Phase II study of paclitaxel and radiotherapy followed by surgical resection for gastric adenocarcinoma. Study protocol. Available at http.//cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
121. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13:2463-2655.
122. Bishop JF, Dewar J, Tattersall MH. et al. A randomized phase III study of Taxol (paclitaxel) vs CMFP in untreated patients with metastatic breast cancer (abstract 107). Proc Am Soc Clin Oncol 1996;15:110.
123. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Natl Cancer lnst Monogr 1993;15:161-169.
124. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Gonte P, Klaassen U, Namer M, Bonneterre J, Furnoleau P, Winograd B. Multicenter, randomized trial of two doses of paclitaxel in metastatic breast cancer. J Clin Oncol 1996;14:1858-1867.
125. Formenti SC, Symmans WF, Volm M, Skinner K, Cohen D, Spicer D, Danenberg PV. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 1999;9(2 suppl 1):34-42.
126. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA. Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-79.
127. GOG-9804. Phase I/II study of extended field radiation therapy with concurrent paclitaxel and cisplatin chemotherapy in patients with cancer of the cervix metastatic to the para-aortic lymph nodes. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
128. GOG-9803. Phase I/II study of whole pelvic radiation therapy in combination with paclitaxel and cisplatin chemotherapy in patients with cervical cancer limited to the pelvis. Study protocol. Available at http:// cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
129. UCCRC-8270. Phase I study of concomitant chemoradiotherapy with vinorelbine and paclitaxel in patients with advanced pelvic malignancies. Study protocol. Available at http://cancernet.nci.nih.gov/cgi-gin. Accessed February 16, 1999.
130. RTOG-9708. Phase II study of adjuvant postoperative irradiation combined with cisplatin and paclitaxel chemotherapy following total abdominal hysterectomy and bilateral salpingophorecotomy in patients with high risk endometrial cancer. Study protocol available at http://cancernet.nci.nih.gov/cgi-bin. Accessed February 16, 1999.
131. Chougule P, Wehbe T, Leone L, et al. Concurrent Taxol, carboplatin, and radiotherapy in advanced head and neck cancer: A phase II study, (abstract 898) Proc Am Soc Clin Oncol 1996;15:317.
132. Choy H. Concurrent paclitaxel, carboplatin, and radiation therapy for non-small cell lung cancer. The Fox Chase Cancer Center and Free University Hospital Paclitaxel Investigators Workshop and Consensus Conference. St. Thomas, US Virgin Islands. March 26-28, 1998. Oral Presentation.
133. Belani CP, Aisner J, Bahri S, Jett J, Day R, Capazolli MJ, Hiponia D, Engstrom C. Chemoradiotherapy in non-small cell lung cancer: Paclitaxel/carboplatin/ radiation in regionally advanced disease. Semin Oncol 1996;23(Suppl 16): 113-116.
134. Lau D. Concurrent twice-weekly paclitaxel, carboplatin, and radiation for stage III non-small cell lung cancer. The Fox Chase Cancer Center and Free University Hospital Paclitaxel Investigators Workshop and Con-sensus Conference. St. Thomas, US Virgin Islands. March 26-28, 1998. Oral Presentation.
135. Meluch AA, Hainsworth JD, Gray JR, et al. Preoperative therapy with paclitaxel, carboplatin, 5-FU, and radiation in the treatment of local esophageal cancer (abstract 995). Proc Am Soc Clin Oncol 1998;17: 259a.